To include your compound in the COVID-19 Resource Center, submit it here.

XLRS: Phase I/II data

Top-line data from 8 patients with XLRS in an open-label, U.S. Phase I/II trial showed that low- and mid-dose

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE